DELCATH SYSTEMS INC
NASDAQ: DCTH (Delcath Systems, Inc.)
Last update: 1 hour ago9.13
-0.07 (-0.76%)
| Previous Close | 9.20 |
| Open | 9.24 |
| Volume | 185,083 |
| Avg. Volume (3M) | 479,874 |
| Market Cap | 322,414,272 |
| Price / Earnings (TTM) | 130.43 |
| Price / Earnings (Forward) | 25.77 |
| Price / Sales | 4.39 |
| Price / Book | 2.93 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | -26.38% |
| Operating Margin (TTM) | 3.24% |
| Diluted EPS (TTM) | -0.450 |
| Quarterly Revenue Growth (YOY) | 530.30% |
| Total Debt/Equity (MRQ) | 1.27% |
| Current Ratio (MRQ) | 15.95 |
| Operating Cash Flow (TTM) | -6.89 M |
| Levered Free Cash Flow (TTM) | -7.11 M |
| Return on Assets (TTM) | -1.51% |
| Return on Equity (TTM) | -28.13% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Delcath Systems, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -2.5 |
| Average | 1.00 |
|
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 2.73% |
| % Held by Institutions | 45.84% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Rosalind Advisors, Inc. | 31 Dec 2025 | 3,300,389 |
| Goldman Sachs Group Inc | 31 Dec 2025 | 587,678 |
| Divisadero Street Capital Management, Lp | 31 Dec 2025 | 499,796 |
| Exoduspoint Capital Management, Lp | 31 Dec 2025 | 496,705 |
| Propel Bio Management, Llc | 31 Dec 2025 | 438,509 |
| Ikarian Capital, Llc | 31 Dec 2025 | 431,251 |
| Citadel Advisors Llc | 31 Dec 2025 | 368,865 |
| Renaissance Technologies Llc | 31 Dec 2025 | 361,599 |
| Private Wealth Advisors, Llc | 31 Dec 2025 | 290,481 |
| Palisades Investment Partners, Llc | 31 Dec 2025 | 267,138 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (HC Wainwright & Co., 228.59%) | Buy |
| Median | 24.50 (168.35%) | |
| Low | 19.00 (BTIG, 108.11%) | Buy |
| Average | 24.50 (168.35%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 9.67 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 26 Feb 2026 | 19.00 (108.11%) | Buy | 9.00 |
| HC Wainwright & Co. | 09 Jan 2026 | 30.00 (228.59%) | Buy | 10.34 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 27 Jan 2026 | Announcement | Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference |
| 21 Jan 2026 | Announcement | Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 09 Jan 2026 | Announcement | Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results |
| 31 Dec 2025 | Announcement | Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |